We are live on
!
Find out more
Boston Trust Walden Portfolio holdings
AUM
$13.1B
Turnover
6.42%
1-Year Est. Return
24.63%
This Fund
S&P 500
This Quarter
Est. Return
+3.74%
1 Year Est. Return
+24.63%
3 Year Est. Return
+61.41%
5 Year Est. Return
+82.17%
10 Year Est. Return
+348.29%
AUM
$6.22B
AUM Growth
-$194M
(-3%)
Cap. Flow
-$367M
Cap. Flow
% of AUM
-5.9%
Top 10 Holdings %
Top 10 Hldgs %
16.53%
Holding
380
New
29
Increased
159
Reduced
150
Closed
10
Avg Time Held
2.8
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$18M |
| 2 |
Monro
MNRO
|
+$15.1M |
| 3 |
Dentsply Sirona
XRAY
|
+$14.8M |
| 4 |
Hubbell
HUBB
|
+$12.1M |
| 5 |
Northern Trust
NTRS
|
+$8.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$31.3M |
| 2 |
W.W. Grainger
GWW
|
+$26.8M |
| 3 |
Verizon
VZ
|
+$21.9M |
| 4 |
IPG Photonics
IPGP
|
+$18.2M |
| 5 |
Coherent Inc
COHR
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.36% |
| 2 | Healthcare | 17.82% |
| 3 | Technology | 14.53% |
| 4 | Industrials | 13.36% |
| 5 | Consumer Discretionary | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
326
Franklin Templeton
BEN
$15.9B
| $597K | 0.01% |
13,330
-22,100
| -62% | -$944K |
2013 Q2
16 quarters
|
|
327
Toronto Dominion Bank
TD
$196B
| $585K | 0.01% |
+11,603
| New | +$560K |
2017 Q2
0 quarters
|
|
328
Southern Company
SO
$103B
| $561K | 0.01% |
11,711
+2,016
| +21% | +$101K |
2013 Q2
16 quarters
|
|
329
iShares Core S&P Mid-Cap ETF
IJH
$123B
| $557K | 0.01% |
16,010
+2,250
| +16% | +$77.7K |
2017 Q1
1 quarter
|
|
330
Target
TGT
$71.2B
| $541K | 0.01% |
10,352
+77
| +0.7% | +$4.21K |
2013 Q2
16 quarters
|
|
331
Marsh
MRSH
$89B
| $540K | 0.01% |
6,922
| – | – |
2013 Q2
16 quarters
|
|
332
Cabot Corp
CBT
$3.9B
| $535K | 0.01% |
+10,014
| New | +$549K |
2017 Q2
0 quarters
|
|
|
CERN
333
DELISTED
Cerner Corp
CERN
| $498K | 0.01% |
7,497
+2,297
| +44% | +$147K |
2016 Q2
4 quarters
|
|
334
Regeneron Pharmaceuticals
REGN
$82B
| $491K | 0.01% |
1,000
| – | – |
2013 Q2
16 quarters
|
|
335
Varex Imaging
VREX
$784M
| $474K | 0.01% |
14,011
-2,350
| -14% | -$80K |
2017 Q1
1 quarter
|
|
336
Thermo Fisher Scientific
TMO
$258B
| $472K | 0.01% |
2,708
-75
| -3% | -$12.6K |
2013 Q2
16 quarters
|
|
337
iShares Russell 1000 ETF
IWB
$49.2B
| $464K | 0.01% |
3,432
| – | – |
2016 Q4
2 quarters
|
|
338
Duke Energy
DUK
$92.7B
| $458K | 0.01% |
5,484
+1,133
| +26% | +$95.2K |
2017 Q1
1 quarter
|
|
|
RDS.A
339
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $445K | 0.01% |
8,369
+722
| +9% | +$38.3K |
2013 Q2
16 quarters
|
|
340
L3Harris
LHX
$44.8B
| $435K | 0.01% |
+3,987
| New | +$439K |
2017 Q2
0 quarters
|
|
341
Broadcom
AVGO
$1.64T
| $420K | 0.01% |
18,010
+8,000
| +80% | +$186K |
2017 Q1
1 quarter
|
|
342
iShares MSCI EAFE ETF
EFA
$76.9B
| $416K | 0.01% |
+6,373
| New | +$412K |
2017 Q2
0 quarters
|
|
343
Northrop Grumman
NOC
$71B
| $408K | 0.01% |
1,590
| – | – |
2013 Q2
16 quarters
|
|
344
DuPont de Nemours
DD
$17.8B
| $397K | 0.01% |
2,486
-230
| -8% | -$36.5K |
2013 Q3
15 quarters
|
|
345
Unilever
UL
$139B
| $382K | 0.01% |
6,278
+112
| +2% | +$6.68K |
2016 Q2
4 quarters
|
|
346
Chipotle Mexican Grill
CMG
$38.7B
| $369K | 0.01% |
44,400
-6,550
| -13% | -$60.8K |
2013 Q2
16 quarters
|
|
347
Ingredion
INGR
$6.13B
| $358K | 0.01% |
3,000
-500
| -14% | -$59.4K |
2013 Q2
16 quarters
|
|
348
iShares MSCI USA Quality Factor ETF
QUAL
$48.9B
| $352K | 0.01% |
4,727
| – | – |
2016 Q4
2 quarters
|
|
349
Boston Scientific
BSX
$64B
| $333K | 0.01% |
+12,002
| New | +$319K |
2017 Q2
0 quarters
|
|
350
Royal Caribbean
RCL
$74.9B
| $328K | 0.01% |
+3,000
| New | +$318K |
2017 Q2
0 quarters
|
|
Similar funds
Boston Trust Walden's Q2 2017 Portfolio in Review
As of Q2 2017, Boston Trust Walden held 380 positions worth $6.22B, down 3% from $6.42B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Boston Trust Walden withdrew a net $367M in Q2 2017, closing 10 positions and reducing 150 holdings. Its most notable exit was Air Methods Corp, an estimated $15.4M position sold in full.
By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 19% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Boston Trust Walden opened a new position in Monro worth $12.7M.
- Boston Trust Walden's largest Q2 2017 buy was Monro: 303,868 shares worth $12.7M.
- Boston Trust Walden added most to Alphabet (Google) Class C in Q2 2017, an estimated $18M increase.
- Boston Trust Walden's biggest Q2 2017 reduction was CR Bard Inc., cutting an estimated $31.3M.
- Boston Trust Walden fully exited Air Methods Corp in Q2 2017, selling an estimated $15.4M.
- Boston Trust Walden's ten largest holdings make up 17% of its $6.22B portfolio in Q2 2017.
- Boston Trust Walden opened 29 new positions and closed 10 in Q2 2017.
- Boston Trust Walden's portfolio value fell 3% quarter-over-quarter to $6.22B.
Based on Boston Trust Walden's 13F filing for Q2 2017, filed 19 Jul 2017.